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Background/Aims: Limited data are available regarding 
psychosocial distress at the time of diagnosis of ulcerative 
colitis (UC). We investigated the psychosocial burden and 
factors related to poor health-related quality of life (HRQL) 
among patients newly diagnosed with moderate-to-severe UC 
who were affiliated with the nationwide prospective cohort 
study. Methods: Within the first 4 weeks of UC diagnosis, 
all patients were assessed using the Hospital Anxiety and 
Depression Scale (HADS), Work Productivity and Activity 
Impairment questionnaire, Inflammatory Bowel Disease 
Questionnaire (IBDQ), and 12-Item Short Form (SF-12) 
health survey. A multiple linear regression model was used 
to identify factors associated with HRQL. Results: Between 
August 2014 and February 2017, 355 patients completed 
questionnaires. Significant mood disorders requiring 
psychological interventions, defined by a HADS score ≥11, 
were identified in 16.7% (anxiety) and 20.6% (depression) 
of patients. Patients with severe disease were more likely to 
have presenteeism, loss of work productivity, and activity loss 
than those with moderate disease (all p<0.05). Significant 
mood disorders had the strongest negative relationship 
with total IBDQ score, which indicates disease-specific 
HRQL (β coefficient: –22.1 for depression and –40.0 for 
anxiety, p<0.001). The scores of all SF-12 dimensions, 
which indicate general HRQL, were remarkably decreased 
in the study population compared indirectly with previously 
reported scores in the general population. The Mayo score, 
C-reactive protein level, and white blood cell count showed 
significant negative associations with the IBDQ score 
(p<0.05). Conclusions: Psychosocial screening and timely 
interventions should be incorporated into the initial care of 
patients newly diagnosed with UC. (Gut Liver 2020;14:459-
467)
Key Words: Colitis, ulcerative; Patient reported outcome 
measures; Quality of life; Anxiety; Depression
INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory disorder 
with alternating periods of relapse and remission that affects 
the health-related quality of life (HRQL) of affected patients, 
including physical, mental, and social well-being.1,2 Therefore, 
HRQL and other patient-reported outcomes (PROs) are now 
accepted as important endpoints in clinical trials and as 
treatment targets in real practice for UC and other inflammatory 
bowel diseases (IBDs).3,4 Previous studies have reported that 
HRQL in UC is adversely affected by several factors, including 
patient’s demographics (low socioeconomic status or female 
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sex), disease characteristics (high disease activity and frequent 
relapses), daily symptoms and impaired activities.1,5-9 In addition, 
it has been suggested that comorbid psychological disorders 
such as anxiety and depression have a negative impact on 
HRQL in UC.10,11 However, several unanswered questions remain 
regarding psychosocial issues in UC.
First, there is a lack of information on the extent of the psy-
chosocial burden in newly-diagnosed patients with UC. Given 
diagnostic delay and disease activity, patients with UC often 
have serious psychosocial problems at the time of diagnosis.12,13 
However, limited data are available regarding the unmet psy-
chosocial needs of newly-diagnosed patients with UC.14 More-
over, it is uncertain what comprises the major determinants of 
HRQL in UC. Finally, available data on the PROs of non-Cau-
casian patients with UC are also scarce.15,16 The incidence and 
prevalence of UC in Asian countries have been rapidly increas-
ing;17-19 despite this, psychosocial assessments are overlooked in 
practice, and only a few studies have addressed these issues.7,20,21
In this background, we aimed to comprehensively quantify 
the burden of psychosocial distress and to identify significant 
predictors affecting HRQL among newly-diagnosed patients 
with UC. All patients were affiliated with the MOSAIK (moder-
ate-to-severe ulcerative colitis in Korea) cohort study. It is a na-
tionwide, prospective inception cohort study, the aims of which 
is to reveal the natural course of disease in patients with newly-
diagnosed active (moderate-to-severe) UC. We prospectively 
collected comprehensive PRO data via a patient survey and 
clinical data at regular intervals.
MATERIALS AND METHODS
1. Study population and design
This is an ongoing multicenter, prospective, hospital-based, 
observational cohort study of newly-diagnosed patients with 
moderate-to-severe UC recruited from 30 academic teaching 
hospitals in Korea.22 Inclusion criteria were as follows: aged ≥7 
years at the time of enrollment; newly-diagnosed with mod-
erate-to-severe UC at tertiary referral hospital within 4 weeks 
prior to enrollment. If a patient was to be included after a pri-
mary or secondary hospital diagnosis, they had to have received 
a diagnosis in a tertiary referral hospital within 8 weeks from a 
primary or secondary hospital; willingness to participate in the 
study by providing the informed consent. Patients were exclud-
ed, if they met at least one of the following criteria: participants 
in an interventional clinical trial with systemic corticosteroid, 
biologics (including, but not limited to, infliximab, golimumab, 
adalimumab, vedolizumab and etc.) or other drugs (including, 
but not limited to, sulfasalazine, mesalamine, azathioprine, to-
facitinib and etc.) for UC; having experienced colectomy such 
as subtotal colectomy with ileorectostomy or colectomy with 
ileoanal pouch, Koch pouch, or ileostomy for UC; a current di-
agnosis of indeterminate colitis, or current diagnosis or history 
of Crohn’s disease.
Diagnosis was based on symptoms consistent with UC last-
ing for more than 4 weeks, according to international criteria.23 
To establish a diagnosis, at least three of the following four 
criteria were met: a history of diarrhea, blood or pus in stools, 
macroscopic appearance on endoscopy, with persistent mucosal 
inflammation affecting the rectum in continuity with part or 
all of the colon, microscopic features on biopsy consistent with 
UC, and no suspicion of Crohn’s disease or indeterminate colitis. 
Infectious and other acute or chronic non-IBD conditions were 
excluded from the study.
The disease severity of moderate-to-severe UC was defined 
according to the Mayo scale; active UC was defined as a full 
Mayo score of 6–12 points (6–10 points for moderate; ≥11 for 
severe) and a Mayo endoscopic subscore of ≥2 points on colo-
noscopy or flexible sigmoidoscopy.24,25 Comprehensive clinical 
data were prospectively collected from all participants as fol-
lows: demographics, comorbidities, body mass index, perinatal 
history, vaccination history, surgical history, familial history 
of IBD in first-degree relatives, extraintestinal manifestations, 
disease-related symptoms, and laboratory tests.
2. Patient-reported outcome measurement tools
All patients were requested to complete four self-question-
naires within the first 4 weeks of diagnosis, including the Hos-
pital Anxiety and Depression Scale (HADS) to assess emotional 
health, Work Productivity and Activity Impairment (WPAI) 
questionnaire to assess work disability in UC, and Inflammatory 
Bowel Disease Questionnaire (IBDQ) and 12-Item Short Form 
(SF-12) health survey to assess disease-specific and generic 
HRQL.
3. Assessment of psychological distress
Anxiety and depression symptoms were assessed using the 
two types of validated Korean version of HADS, each called 
HADS-Anxiety (HADS-A) and HADS-Depression (HADS-
D).26,27 They are 14-item self-reported scale designed to measure 
depression and anxiety symptoms in patients with a physical 
illness. Each item on the questionnaire is given a score of 0-3, 
with higher scores representing a higher level of anxiety or de-
pression. Severity is classified as follows: score of 0–7 (normal), 
8-10 (mild), 11–14 (moderate), and ≥15 (severe). A score ≥11 
(each of HADS-A≥11, HADS-D≥11) is highly suggestive of a 
significant mood disorder and indicates a low threshold for pur-
suing psychological intervention.28 
4. Assessment of work disability
Work productivity was assessed using questionnaire for UC 
(WPAI:UC, Korean-Korea v2.0) which consists of six questions 
that focus on the previous 7 days. These six questions are com-
bined into four items: hours of work missed due to the disease 
(absenteeism), degree of reduced productivity while working 
Moon JR, et al: Psychosocial Distress in Newly-Diagnosed UC  461
(presenteeism), regular daily activities (activity impairment) and 
overall work impairment. The scores range from 0% to 100% 
with a higher score indicating greater activity impairment and 
less productivity.29 
5. Assessment of HRQL
IBDQ is a widely used disease-specific questionnaire that 
measures the HRQL in patients with IBD.30 The validated Korean 
version of IBDQ consists of 32-items that explores four dimen-
sions: bowel symptoms (10 items), systemic symptoms (5 items), 
emotional function (12 items) and social function (5 items).31 
The total score on this questionnaire ranges from 32 to 224 with 
higher scores indicating a better quality of life. 31,32
SF-12 is a simplified version of the SF-36 and is one of the 
most popular self-reported multifunctional generic measures 
of HRQL.33 It is composed of 12 items that assess eight health 
concepts including (1) physical functioning, (2) role-physical, (3) 
bodily pain, (4) general health, (5) vitality, (6) social functioning, 
(7) role-emotional, and (8) mental health. Scores of the eight 
scales were calculated according to the manual of scoring into 
the 0 to 100 range.34 A higher SF-12 scores indicate better qual-
ity of life. The scores of all SF-12 items in the study cohort were 
indirectly compared with those of data from the general Korean 
population in a previous published paper.35
6. Outcome measurements and statistical analysis
The primary outcome of our study was to estimate the burden 
of psychosocial distress at the time of disease diagnosis in the 
study cohort. Descriptive statistics for continuous variables 
are presented as means with standard deviation (SD), and 
dichotomous variables are presented as frequencies with 
percentages in parentheses. The PRO measures were compared 
using the Mann-Whitney U-test or t-test, where appropriate by 
disease severity on baseline. To identify factors independently 
Table 1. Demographics and Disease Characteristics of the Study Cohort
Characteristics No. Category Value
Age (yr) at diagnosis 355 37.6±15.2
Sex 355 Male/female 210 (59.2)/145 (40.8)
Body mass index (kg/m2) 344 22.4±3.2
Smoking 342 Never or former 312 (91.2)
Current 30 (8.8)
Alcohol 345 Never or past 191 (55.3)
Current 154(44.6)
Currently employed 348 Yes/no 169 (48.6)/179 (51.4)
Family income* 309 Low (<200) 83 (26.9)
Middle (≥200 and <400) 139 (45.0)
High (≥400) 87 (28.2)
Family history of IBD 334 UC/CD/others 12 (3.6)/1 (0.3)/3 (0.9)
Symptoms duration† 354 15.9±36.1
<4 wk 142 (40.1)
≥4 wk 212 (59.9)
Total Mayo score 355 8.1±1.6
Disease severity‡ 355 Moderate/severe 330 (93.0)/25 (7.0)
Endoscopic severity§ 355 Moderate/severe 255 (71.8)/100 (28.2)
Disease extentII 349 Proctitis 35 (10.0)
Left-sided colitis 162 (46.4)
Extensive colitis 152 (43.6)
ESR, mm/hr 304 20.8±19.3
C-reactive protein, mg/dL 324 2.6±7.3
White cell count, 103/μL 346 12.7±60.2
Hemoglobin, g/dL 347 12.8±2.0
Albumin, g/dL 304 4.0±0.6
Data are presented as the mean±SD or number (%). 
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; ESR, erythrocyte sedimentation rate.
*10,000 Korean Won; †Time between the first development of disease-related symptoms and UC diagnosis; ‡Moderate: total Mayo score 6–10; se-
vere: total Mayo score ≥11; §Moderate: Mayo endoscopic subscore=2; severe: Mayo endoscopic subscore=3; IIMontreal classification. 
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associated with quality of life, we used multiple linear regression 
analysis. The selection of variables included in the multiple 
linear regression model was based on results of the univariate 
analyses (p≤0.1) of the relevant variables. All analyses were 
performed using R software, version 3.4.3 (R foundation for 
Statistical Computing, Vienna, Austria) and SAS software, 
version 9.4 (SAS Institute Inc., Cary, NC, USA). p-values less 
than 0.05 were considered statistically significant.
7. Ethical considerations
The study was conducted according to the Declaration of 
Helsinki and was approved by the institutional review boards 
of all participating hospitals. Written informed consent was 
obtained from all participants. The study was registered at www.
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Fig. 1. Distribution of the study population according to the Hospital 












































Fig. 2. Assessment of work productivity and activity impairment 
using the Work Productivity and Activity Impairment-Ulcerative 
Colitis (WPAI-UC) questionnaire. Absenteeism: percentage of work 
time missed; presenteeism: percentage of impairment while work-
ing; percentage of overall work impairment=(Q2/(Q2+Q4)+[(1–(Q2/
(Q2+Q4)))×(Q5/10)])×100; percentage of social activity impairment= 
(Q6/10)×100. Q, questionnaire item.
Table 2. Mean Values of Each Patient-Reported Outcome Measure
PROs Category No. Overall (n=355)
Disease severity
p-value
Moderate (n=330)* Severe (n=25)†
HADS Depression 349 6.6±4.5 6.5±4.4 8.9±5.2 0.610
Anxiety 348 6.2±4.4 6.2±4.4 6.6±4.5 0.638
WPAI:UC Absenteeism‡ 149 29.1±36.9 27.3±35.8 54.1±43.5 0.102 
Presenteeism§ 143 37.8±31.4 36.8±30.3 62.2±39.6  0.037
Overall work impairmentII 130 45.5±32.7 44.1±31.9 70.7±37.8  0.048
Social activity impairment¶ 344 46.4±31.2 45.2±31.0 61.2±31.0  0.014
IBDQ Bowel system 344 41.7±13.0 42.0±13.1 36.1±10.9  0.027
Emotional health 347 51.7±14.9 52.0±14.9 46.8±13.6 0.097
Systemic symptoms 347 20.5±6.8 20.7±6.8 17.0±6.0  0.009
Social function 309 23.2±7.7 22.8±7.9 18.0±6.8  0.003
Total score 305 137.3±38.8 137.5±39.0 117.9±33.2  0.002
Data are presented as the mean±SD. 
PRO, patient-reported outcome; HADS, Hospital Anxiety and Depression Scale; WPAI, Work Productivity and Activity Impairment; UC, ulcerative 
colitis; IBDQ, Inflammatory Bowel Disease Questionnaire. 
*Total Mayo score 6–10 points; †Total Mayo score ≥11; ‡Absenteeism: percentage of work time missed=(Q2/[Q2+Q4])×100; §Presenteeism: percent-
age of impairment while working=(Q5/10)×100; IIPercentage of overall work impairment=(Q2/(Q2+Q4)+[(1–(Q2/(Q2+Q4)))×(Q5/10)])×100; ¶Per-
centage of social activity impairment=(Q6/10)×100; Q, questionnaire item.
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RESULTS
1. Demographics and clinical characteristics of the study 
population
Between August 2014 and February 2017, 368 patients were 
considered eligible for and invited to participate in this study. 
Of them, 355 patients who met eligibility criteria were enrolled 
and completed the questionnaires. The baseline demographics 
and clinical characteristics are described in Table 1. The mean 
age at the time of diagnosis was 37.6 years, and the peak age of 
diagnosis was in the third decade of life (29.6%). The proportion 
of male patients was 59.2%, with a male to female ratio of 1.4:1. 
Sixteen patients (4.8%) had a family history of IBD among their 
first-degree relatives. Approximately half (48.6%) of patients 
were employed at the time of data collection.
The mean duration from symptom onset to diagnosis was 
15.9 (SD, 36.1) weeks; 59.9% of patients firstly began to notice 
UC-related symptoms more than 4 weeks before the diagnosis. 
The mean Mayo score was 8.1 (1.6), and 28.2% of patients had 
severe disease on endoscopy. The disease extent was left-sided 
in 46.4%, extensive colitis in 43.6%, and proctitis in 10.0% 
of patients. The mean levels of serum C-reactive protein and 
hemoglobin were 2.6 mg/dL and 12.8 g/dL, respectively.
2. Psychological comorbidities, work productivity and 
health-related quality of life
The prevalence of comorbid psychiatric illnesses, defined as 
a HADS score ≥8, among the patients was 33.7% for anxiety 
and 41.8% for depression (Fig. 1). Of these, significant mood 
disorders requiring psychological interventions, defined by a 
HADS score ≥11, were identified in 16.7% (anxiety) and 20.6% 
(depression) of patients. There was no significant difference in 
the mean HADS score according to disease severity (Table 2).
Among all respondents of the WPAI:UC, severe disabilities 
(defined as a WPAI:UC score ≥50%) were reflected as absentee-

























































































Fig. 3. 12-Item Short Form (SF-12) 
results in the study cohort in compari-
son with those previously published 
for the general Korean population.33
PF, physical functioning; RP, role-
physical; BP, bodily pain; GH, gen-
eral health; VT, vitality; SF, social 
functioning; RE, role-emotional; MH, 
mental health; MOSAIK, moderate-
to-severe ulcerative colitis in Korea.
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and social activity (53.5%), respectively (Fig. 2). Patients with 
severe disease were more likely to have presenteeism, overall 
work impairment, and social activity impairment, when com-
pared to those with moderate disease (62.2% vs 36.8%; 70.7% 
vs 44.1%; 61.2% vs 45.2%, all p<0.05).
Fig. 3 shows the mean SF-12 component scores in the study 
cohort in men and women; our data were indirectly compared 
with those obtained from the general Korean population, which 
revealed that our study cohort tended to have a worse HRQL 
than that of the general population.35 With respect to disease-
specific HRQL, patients with severe disease activity reported 
significantly a lower total IBDQ score, compared to those with 
moderate disease activity (117.9 vs 137.5, p<0.05).
3. Factors associated with HRQL
In our multiple regression model, significant mood disorders 
were found to be major determinants of HRQL. The presence 
of both significant depression and anxiety showed the stron-
gest negative relationships with the total IBDQ score (β coeffi-
cient=–22.1 for depression and –40.0 for anxiety, all p<0.001) 
(Table 3) and almost all of the domains of the SF-12 (Supple-
mentary Table 1). The total IBDQ score also had significant neg-
ative relationships with the total Mayo score, serum C-reactive 
protein (CRP) and white blood cell count (β=–4.1, β=–0.5, and 
β=–0.1, respectively; all p<0.05), but positive relationship with 
the hemoglobin level (β=2.3, p=0.02).
DISCUSSION
This large-scale nationwide prospective cohort study in Korea 
clearly show that the burden of psychosocial distress is very 
high among newly-diagnosed patients with UC. The prevalence 
of psychological comorbidities at the given time was as high 
as 33.7% for anxiety and 41.8% for depression. Approximately 
50% of patients reported severe loss of work productivity (46.2%) 
and social activity (53.5%). Higher disease activity at the time of 
diagnosis was more likely to result in loss of work/social activi-
ty and low disease-specific HRQL. Our study also highlights that 
the presence of either significant anxiety or depression (either 
HADS-A or HADS-D≥11) had strong negative impact on both 
disease-specific and generic HRQL. These data strongly indicate 
a need for point-of-care screening and timely interventions for 
psychosocial distress among newly-diagnosed patients with UC, 
particularly moderate-to-severe UC.
Generally, patients with IBDs including UC more frequently 
have greater psychiatric distress, work disability and lower 
HRQL, compared with general population.1,2,6,10,36,37 Although 
the rates of psychiatric distress are generally higher in patients 
with active IBD than inactive IBD,36 there have been no studies 
conducting a comprehensive psychosocial evaluation in a sub-
set of patients with “newly-diagnosed moderate to severe” UC. 
The prevalence rates of psychiatric comorbidities in the present 
study are comparable with those in a recent French nationwide 
study involving 1,185 patients with IBD (including 462 with 
UC), although there were considerable differences in the study 
populations (HADS-D ≥8, 41.8% in our study vs 48.5% in the 
UC subgroup of French cohort; HADS-A ≥8, 33.7% in our 
study vs 28.1% in the UC subgroup of French cohort).37 Given 
the disease activity (moderate-to-severe) of our study cohort, 
the reported rates of psychological comorbidities in this study 
seem reasonable. Of interest, approximately 20.0% of patients 
had clinically significant mood disorders requiring psychologi-
cal interventions, suggesting the high unmet need of newly-
diagnosed patients with moderate-to-severe UC. Psychological 
comorbidity is a factor contributing to non-adherence to medi-
cation and thus leading to adverse outcomes in UC.38,39 In this 
regard, our results also suggest that psychological screening 
and timely interventions should be integrated into the initial 
management of UC. Unfortunately, only a minority of “at risk” 
patients with IBD are believed to receive proper psychological 
interventions. In a Dutch study, over 60% of IBD patients with 
psychological comorbidity symptoms did not receive adequate 
care.40 In the National Audit report in the United Kingdom, only 
12.0% of adult IBD services have a clinical resource for psycho-
logical services via a defined referral process.41 Therefore, inte-
grated multidisciplinary care models may be helpful to deliver 
timely psychological services to patients with IBD.42,43
We provided objective indicators of work disability during 
the early course of UC, specifically within the first 4 weeks of 
diagnosis with active UC. We found that work disability was a 
common and serious problem in this population. The prevalence 
of severe disability was as high as 28.2% (absenteeism), 40.6% 
(presenteeism), 46.2% (work productivity), and 53.5% (social 
activity). Patients with severe disease were more likely to have 
a high level of work disability in terms of presenteeism and im-
pairment of overall work and social activity. The prevalence of 
Table 3. Multiple Linear Regression Analysis to Identify Factors As-







Hemoglobin, g/dL 2.3 0.022
CRP, mg/dL –0.5 0.038
WBC, 103/μL –0.1 0.003
Disease severity* –4.1 0.002
IBDQ, Inflammatory Bowel Disease Questionnaire; HADS-D, Hospital 
Anxiety and Depression Scale-Depression; HADS-A, Hospital Anxiety 
and Depression Scale-Anxiety; CRP, C-reactive protein; WBC, white 
blood cell.
*Total Mayo score. Reference variables: HADS-D/A (<11), disease se-
verity (moderate).
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work productivity loss and social activity impairment in our co-
hort (severe ≥50%: 46.2% and 53.5%, respectively) are consid-
erably higher than those in the UC subgroup of French cohort 
(18.1% and 33.1%), suggesting that work disability in patients 
with newly-diagnosed UC is a serious problem requiring social 
support.37 Recently, the impact on daily activities (disability) was 
suggested as a key factor contributing to overall UC severity,44 
suggesting that the risk stratification by disability grade for an 
individual patient could guide personalized management plans 
for UC. Future prospective studies are expected to address this 
issue.
As expected, the HQRL among the MOSAIK cohort was se-
verely impaired at baseline. The scores of all SF-12 dimensions, 
reflecting generic HRQL, were remarkably lower, compared with 
previously reported scores in the Korean general population (Fig. 
3). The mean total IBDQ score in our study was much lower 
than those in other population-based IBD cohorts: 137.3 versus 
183.0 in the Inflammatory Bowel Disease in South-East Norway 
population cohort;45 versus 198.3 in the Spanish study.11 Our 
results seem reasonable, given that disease activity is a deter-
mining factor of the HRQL in UC. Importantly, we confirmed 
that the presence of either significant anxiety or depression 
was a major contributing factor for both disease-specific and 
generic HRQL in our cohort. Comorbid psychological disorders 
had very strong negative associations with the total IBDQ score 
(Table 3) and almost all SF-12 domains (Supplementary Table 
1). These results strongly suggest that complex biopsychosocial 
care should be provided as early as possible, particularly in pa-
tients with both psychological disorders and poor HRQL.46 To 
accomplish this goal, it is imperative to implement an adequate 
screening process in routine practice.47,48
We also found that the IBDQ score had significant negative 
correlations with the Mayo score, CRP level, and white blood 
cell count, but a positive association with the hemoglobin level 
(all p<0.05). These data suggest that common laboratory mark-
ers and clinical activity indices (i.e., Mayo score) provide useful 
predictors for disease-specific HRQL in patients with UC. We 
expected a longer duration between onset of symptom to di-
agnosis (i.e., diagnostic delay) would be one of the significant 
associated factors of low HRQL. The mean duration between 
symptom onset and diagnosis was approximately 4 months in 
this study, which was comparable with the previous findings 
from a Caucasian population.49 Unexpectedly, the delayed di-
agnosis was not associated with either HRQLs, disease-specific 
or general measurement tools, according to the multiple linear 
regression analysis.
Our study had several unique strengths. First, the study popu-
lation was affiliated with a well-designed nationwide ongoing 
prospective cohort (MOSAIK), from a country where the inci-
dence and prevalence of UC have rapidly increased in recent 
years.17-19 The data consistency has been managed tightly under 
strict diagnostic criteria, quality controls, and data cleaning. Ad-
ditionally, as stated above, the PROs are now accepted as one of 
the major end points of clinical trials.3 The MOSAIK cohort in-
cludes only newly-diagnosed patients with moderate-to-severe 
UC, who are potential candidates for future major clinical trials. 
Our detailed PRO results at the time of diagnosis are meaning-
ful for future clinical trials as well as routine practice. However, 
our study also had several weaknesses. The study population 
was comprised only of patients with moderate-to-severe activity 
from academic referral hospitals, after excluding patients with 
mild activity or those who were stationed at private clinics/
community hospitals. In addition, we currently do not have lon-
gitudinal follow-up data of the PROs; it is being collected and 
will be presented later.
In conclusion, the present study clearly demonstrated that the 
burden of psychosocial distress was very high among newly-
diagnosed patients with active UC, and that significant mood 
disorders were the major determinants of disease-specific HRQL. 
Complex biopsychosocial care, including point-of-care psy-
chological screening and interventions, should be integrated 
into the initial management of newly-diagnosed patients with 
moderate-to-severe UC.
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